ST. LOUIS, Sept. 13, 2017 -- Amdocs (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today announced that it entered into an agreement pursuant to which Amdocs will acquire prime commercial land located in Ra’anana, Israel. Closing of the transaction is subject to customary closing conditions, as well as waiver of a third party’s rights with respect to such land.
Amdocs intends to use the land to be acquired under the agreement to serve as the site of a new campus that will provide an advanced, optimal working environment that can fully meet the needs of Amdocs Israel, an Amdocs company, and its employees, and support the company’s future growth.
Amdocs is currently evaluating various alternatives with respect to the future development and construction of the new campus, including structures for ownership or long-term lease arrangements. The acquisition costs are not expected to have a material impact on Amdocs’ cash position or operating results.
Supporting Resources
- Keep up with Amdocs news by visiting the company’s website
- Subscribe to Amdocs’ RSS Feed and follow us on Twitter, Facebook, LinkedIn and YouTube
About Amdocs
Amdocs is a leading software and services provider to the world’s most successful communications and media companies. As our customers reinvent themselves, we enable their digital and network transformation through innovative solutions, delivery expertise and intelligent operations. Amdocs and its 25,000 employees serve customers in over 85 countries. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $3.7 billion in fiscal 2016.
For more information, visit Amdocs at www.amdocs.com.
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs’ intention to complete this transaction and its impact on Amdocs’ results in future quarters. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the possibility that a third party’s rights with respect to such land shall not be waived (as to which we can provide no assurances), effects of general economic conditions, Amdocs’ ability to grow in the business markets that it serves, Amdocs’ ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, the Company specifically disclaims any obligation to do so. These and other risks are discussed at greater length in the Company's filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2016 filed on December 12, 2016 and our quarterly 6-K form furnished on February 13, May 22 and August 14, 2017.
Contact:
Matthew Smith
Head of Investor Relations
Amdocs
314-212-8328
E-mail: [email protected]


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Italy Fines Apple €98.6 Million Over App Store Dominance
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 



